SCHEMBL25337018

SCHEMBL25337018

Cn1c(=O)[nH]c2ccc(F)c(N3CCN(C(=O)OC(C)(C)C)CC3)c21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 4/20 0.41
▸ MAPT P10636 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ CKS1B P61024 1/20 0.39
▸ SKP1 P63208 1/20 0.39
▸ SKP2 Q13309 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ STS P08842 1/20 0.39
▸ MMP2 P08253 1/20 0.38
▸ MMP13 P45452 1/20 0.38
▸ MMP14 P50281 1/20 0.38
▸ ADAMTS5 Q9UNA0 1/20 0.38
▸ MAP4K4 O95819 1/20 0.38
▸ KIT P10721 1/20 0.38
▸ PRMT5 O14744 1/20 0.38
▸ MAPK8 P45983 1/20 0.38
▸ DDB1 Q16531 1/20 0.38
▸ CRBN Q96SW2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26447780 0.88 MEN1 (0.42) GPR119MAPTALDH1A1LMNACKS1B
SCHEMBL25339852 0.88 CNR1 (0.41) GPR119ALDH1A1MEN1KMT2AMMP2
SCHEMBL24846895 0.86 GPR119 (0.42) GPR119MAPTALDH1A1LMNACKS1B
SCHEMBL22848653 0.81 PARP1 (0.45) GPR119MAPTALDH1A1LMNACKS1B
SCHEMBL29502336 0.81 PARP1 (0.45) GPR119MAPTALDH1A1LMNACKS1B
SCHEMBL24607326 0.81 THRB (0.47) GPR119MAPTALDH1A1MEN1KMT2A
SCHEMBL29751311 0.81 THRB (0.47) GPR119MAPTALDH1A1MEN1KMT2A
SCHEMBL25338892 0.78 KIT (0.46) GPR119MAPTALDH1A1LMNACKS1B
SCHEMBL31397312 0.78 SMARCA2 (0.44) GPR119ADAMTS5
SCHEMBL24819534 0.78 SMARCA2 (0.44) GPR119ADAMTS5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250011325-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-09 — — US disclosed
EP-4472967-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-12-11 — — EP disclosed
US-12091411-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-09-17 — — US disclosed
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-11-16 — — US disclosed
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-11-16 — — US disclosed
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-11-16 — — US disclosed
WO-2023147594-A2 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
WO-2023147594-A2 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 GPR119 2426/4885MAPT 2459/4885ALDH1A1 2776/4885
US-20250011325-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 GPR119 2426/4885MAPT 2459/4885ALDH1A1 2776/4885
US-12091411-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 GPR119 2426/4885MAPT 2459/4885ALDH1A1 2776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback